Stock Research: Sumitomo Dainippon Pharma

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Sumitomo Dainippon Pharma

TYO:4506 JP3495000006
35
  • Value
    86
  • Growth
    82
  • Safety
    Safety
    30
  • Combined
    84
  • Sentiment
    8
  • 360° View
    360° View
    35
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Sumitomo Pharma Co Ltd is a pharmaceutical company. It operates in the pharmaceutical industry and regenerative medicine. The company operates in Japan, North America, and Asia. In the last fiscal year, the company had a market cap of $2729 million, profits of $1637 million, revenue of $2660 million, and 3832 employees.

more

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sumitomo Dainippon Pharma are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Sumitomo Dainippon Pharma. The consolidated Value Rank has an attractive rank of 86, which means that the share price of Sumitomo Dainippon Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 86% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 82, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 8. Professional investors are more confident in 92% other stocks. Worryingly, the company has risky financing, with a Safety rank of 30. This means 70% of comparable companies have a safer financing structure than Sumitomo Dainippon Pharma. ...read more

more
Index
Nikkei 225
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
86 30 66 97
Growth
82 88 21 7
Safety
Safety
30 1 1 49
Sentiment
8 14 1 1
360° View
360° View
35 10 4 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
22 1 1 9
Opinions Change
50 82 31 50
Pro Holdings
n/a 26 1 47
Market Pulse
29 5 3 10
Sentiment
8 14 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
86 30 66 97
Growth
82 88 21 7
Safety Safety
30 1 1 49
Combined
84 18 10 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
68 91 100 95
Price vs. Earnings (P/E)
94 33 97 93
Price vs. Book (P/B)
48 31 97 89
Dividend Yield
65 1 1 68
Value
86 30 66 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
55 22 76 9
Profit Growth
18 86 21 30
Capital Growth
87 76 51 8
Stock Returns
97 98 1 57
Growth
82 88 21 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
23 1 5 22
Refinancing
18 1 1 77
Liquidity
86 7 10 51
Safety Safety
30 1 1 49

Similar Stocks

Discover high‑ranked alternatives to Sumitomo Dainippon Pharma and broaden your portfolio horizons.

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

NGK Insulators

TYO:5333
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Inpex

TYO:1605
Country: Japan
Industry: Oil & Gas Production
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: